Risks and benefits from CDK inhibitors for advanced HR1 Her 22 breast cancer

C. Messina, M. Messina, E. Zanardi

Research output: Contribution to journalLetterpeer-review

Original languageEnglish
Pages (from-to)3099-3100
Number of pages2
JournalAnnals of Oncology
Issue number12
Publication statusPublished - Dec 1 2017

ASJC Scopus subject areas

  • Hematology
  • Oncology

Cite this